Skip Nav Destination
Issues
1 October 2022
-
Cover Image
Cover Image
The cover shows a cerebellar section from a mouse-bearing medulloblastoma treated with radiation and an OLIG2 inhibitor. Immunofluorescent staining shows the combination treatment eliminated most tumor cells, but some cancer stem-like cells (red) remained post-treatment. For the details, see the article by Xu and colleagues on page 4278 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer
Elizabeth S. Duke; Amy K. Barone; Somak Chatterjee; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Emasenyie Isikwei; Hong Zhao; Youwei Bi; Jiang Liu; Nam Atiqur Rahman; Emily Wearne; John K. Leighton; Maritsa Stephenson; Idara Ojofeitimi; Barbara Scepura; Abhilasha Nair; Richard Pazdur; Julia A. Beaver; Harpreet Singh
Special Report
Research Briefs: Clinical Trial Brief Reports
Clinical Trials: Targeted Therapy
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Jung-Min Lee; Richard G. Moore; Sharad Ghamande; Min S. Park; John P. Diaz; Julia Chapman; James Kendrick; Brian M. Slomovitz; Krishnansu S. Tewari; Elizabeth S. Lowe; Tsveta Milenkova; Sanjeev Kumar; Mike Dymond; Jessica Brown; Joyce F. Liu
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
Manuel Weber; David Kersting; Burkhard Riemann; Tim Brandenburg; Dagmar Führer-Sakel; Frank Grünwald; Michael C. Kreissl; Henning Dralle; Frank Weber; Kurt Werner Schmid; Ken Herrmann; Walter Jentzen; Hong Grafe; Christoph Rischpler; Sarah Theurer; Andreas Bockisch; James Nagarajah; Wolfgang P. Fendler
Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
Moritz Fürstenau; Jonathan Weiss; Adam Giza; Fabian Franzen; Sandra Robrecht; Anna-Maria Fink; Kirsten Fischer; Christof Schneider; Eugen Tausch; Stephan Stilgenbauer; Matthias Ritgen; Anke Schilhabel; Monika Brüggemann; Barbara Eichhorst; Michael Hallek; Paula Cramer
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Feng Wang; Ming-Ming He; Jian Xiao; Yan-Qiao Zhang; Xiang-Lin Yuan; Wei-Jia Fang; Yan Zhang; Wei Wang; Xiao-Hua Hu; Zhi-Gang Ma; Yi-Chen Yao; Zhi-Xiang Zhuang; Fu-Xiang Zhou; Jie-Er Ying; Ying Yuan; Qing-Feng Zou; Zeng-Qing Guo; Xiang-Yuan Wu; Ying Jin; Zong-Jiong Mai; Zhi-Qiang Wang; Hong Qiu; Ying Guo; Si-Mei Shi; Shuang-Zhen Chen; Hui-Yan Luo; Dong-Sheng Zhang; Feng-Hua Wang; Yu-Hong Li; Rui-Hua Xu
Clinical Trials: Immunotherapy
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
Nai-Jung Chiang; Kien Thiam Tan; Li-Yuan Bai; Chin-Fu Hsiao; Chung-Yu Huang; Yi-Ping Hung; Chien-Jui Huang; San-Chi Chen; Yan-Shen Shan; Yee Chao; Yi-Hsiang Huang; I-Cheng Lee; Pei-Chang Lee; Yung-Yeh Su; Shu-Jen Chen; Chun-Nan Yeh; Li-Tzong Chen; Ming-Huang Chen
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Arnon Nagler; Maud Ngoya; Jacques-Emmanuel Galimard; Myriam Labopin; Martin Bornhäuser; Matthias Stelljes; Jürgen Finke; Arnold Ganser; Herman Einsele; Nicolaus Kröger; Arne Brecht; Wolfgang Bethge; Matthias Edinger; Aleksandr Kulagin; Jakob Passweg; Igor Wolfgang Blau; Ahmet Elmaagacli; Kerstin Schäfer-Eckart; Uwe Platzbecker; Thomas Schroeder; Donald Bunjes; Johanna Tischer; Sonja Martin; Alexandros Spyridonidis; Sebastian Giebel; Bipin Savani; Mohamad Mohty
Precision Medicine and Imaging
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
Eugene J. Pietzak; Karissa Whiting; Preethi Srinivasan; Chaitanya Bandlamudi; Aliya Khurram; Vijai Joseph; Aleksandra Walasek; Emily Bochner; Timothy Clinton; Nima Almassi; Hong Truong; Manuel R. de Jesus Escano; Michal Wiseman; Diana Mandelker; Yelena Kemel; Liying Zhang; Michael F. Walsh; Karen A. Cadoo; Jonathan A. Coleman; Hikmat Al-Ahmadie; Jonathan E. Rosenberg; Gopakumar V. Iyer; David B. Solit; Irina Ostrovnaya; Kenneth Offit; Mark E. Robson; Zsofia K. Stadler; Michael F. Berger; Dean F. Bajorin; Maria Carlo; Bernard H. Bochner
Translational Cancer Mechanisms and Therapy
Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma
Barry M. Berger; Glenn J. Hanna; Marshall R. Posner; Eric M. Genden; Julio Lautersztain; Stephen P. Naber; Catherine Del Vecchio Fitz; Charlotte Kuperwasser
Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
Beryl L. Manning-Geist; Ying L. Liu; Kelly A. Devereaux; Arnaud Da Cruz Paula; Qin C. Zhou; Weining Ma; Pier Selenica; Ozge Ceyhan-Birsoy; Lea A. Moukarzel; Timothy Hoang; Sushmita Gordhandas; Maria M. Rubinstein; Claire F. Friedman; Carol Aghajanian; Nadeem R. Abu-Rustum; Zsofia K. Stadler; Jorge S. Reis-Filho; Alexia Iasonos; Dmitriy Zamarin; Lora H. Ellenson; Yulia Lakhman; Diana L. Mandelker; Britta Weigelt
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC
Hyun Ae Jung; Jinyeong Lim; Yoon-La Choi; Se-Hoon Lee; Je-Gun Joung; Yeong Jeong Jeon; Jae Won Choi; Sumin Shin; Jong Ho Cho; Hong Kwan Kim; Yong Soo Choi; Jae Ill Zo; Young Mog Shim; Sehhoon Park; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Joungho Han; Woong-Yang Park; Jhingook Kim; Keunchil Park
Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma
Xinyi Tang; Zhi-Zhang Yang; Hyo Jin Kim; Theodora Anagnostou; Yue Yu; Xiaosheng Wu; Jun Chen; Jordan E. Krull; Kerstin Wenzl; Patrizia Mondello; Vaishali Bhardwaj; Junwen Wang; Anne J. Novak; Stephen M. Ansell
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
Amanda N. Ruggieri; Mark Yarchoan; Subir Goyal; Yuan Liu; Elad Sharon; Helen X. Chen; Brian M. Olson; Chrystal M. Paulos; Bassel F. El-Rayes; Shishir K. Maithel; Nilofer S. Azad; Gregory B. Lesinski
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
Wolfgang P. Fendler; Kim M. Pabst; Lukas Kessler; Pedro Fragoso Costa; Justin Ferdinandus; Manuel Weber; Maria Lippert; Katharina Lueckerath; Lale Umutlu; Karina Kostbade; Ilektra A. Mavroeidi; Martin Schuler; Marit Ahrens; Christoph Rischpler; Sebastian Bauer; Ken Herrmann; Jens T. Siveke; Rainer Hamacher
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.